Drug approvals in 2021 continued at a pace consistent with prior years, but a large backlog of inspections is slowing some approvals. Cell and gene therapies investment is growing rapidly and promises substantial revenue growth in the coming years. Read about other sectors 2021 FDA approvals ... READ MORE >